Mythili Ramachandran

Mythili Ramachandran

Auto-generated profile, based on publicly available information

Mythili Ramachandran

Department of Biochemistry and Molecular Medicine, University of California-Davis, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
MTMenghuan Tang
Menghuan Tang
KLKai Lin
Kai Lin
MRMythili Ramachandran
Mythili Ramachandran
LLLongmeng Li
Longmeng Li
HZHongye Zou
Hongye Zou
PLPeiyuan Li
Peiyuan Li
Hybrid lipid‒nanoparticle complexes have shown attractive characteristics as drug carriers due to their integrated advantages from liposomes and nanoparticles. Here we developed a kind of lipid-small molecule hybrid nanoparticles (LPHNPs) for imaging and treatment in an orthotopic glioma model. LPHNPs were prepared by engineering the co-assembly of lipids and an amphiphilic pheophorbide a‒quinolinium conjugate (PQC), a mitochondria-targeting small molecule. Compared with the pure nanofiber self-assembled by PQC, LPHNPs not only preserve the comparable antiproliferative potency, but also possess a spherical nanostructure that allows the PQC molecules to be administrated through intravenous injection. Also, this co-assembly remarkably improved the drug-loading capacity and formulation stability against the physical encapsulation using conventional liposomes. By integrating the advantages from liposome and PQC molecule, LPHNPs have minimal system toxicity, enhanced potency of photodynamic therapy (PDT) and visualization capacities of drug biodistribution and tumor imaging. The hybrid nanoparticle demonstrates excellent curative effects to significantly prolong the survival of mice with the orthotopic glioma. The unique co-assembly of lipid and small molecule provides new potential for constructing new liposome-derived nanoformulations and improving cancer treatment.

14 September 2022 in Nanoscale Advances
Verified
Journal Article
Open access
PDF file
MRMythili Ramachandran
Mythili Ramachandran
ZMZhao Ma
Zhao Ma
KLKai Lin
Kai Lin
CSCristabelle De Souza
Cristabelle De Souza
PLPeiyuan Li
Peiyuan Li
Nanomedicine provides a great strategy for emerging chemotherapeutics that can navigate the many biological barriers preventing effective drug delivery to tumors.